Terms: = Head and neck cancer AND NRG1, ENSG00000157168, 3084, SMDF, NDF, HRGA, HRG1, HGL, GGF2, GGF, ARIA AND Treatment
24 results:
1. nrg1 promotes tumorigenesis and metastasis and afatinib treatment efficiency is enhanced by nrg1 inhibition in esophageal squamous cell carcinoma.
Hou G; Niu T; Jia A; Zhang Y; Chen X; Wei H; Jia Y; Xu Y; Li Y; Wang P; Chatterjee A
Biochem Pharmacol; 2023 Dec; 218():115920. PubMed ID: 37989416
[TBL] [Abstract] [Full Text] [Related]
2. Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors.
Garcia-Rendueles MER; Krishnamoorthy G; Saqcena M; Acuña-Ruiz A; Revilla G; de Stanchina E; Knauf JA; Lester R; Xu B; Ghossein RA; Fagin JA
Mol Cancer; 2022 Dec; 21(1):213. PubMed ID: 36476495
[TBL] [Abstract] [Full Text] [Related]
3. YAP1 maintains active chromatin state in head and neck squamous cell carcinomas that promotes tumorigenesis through cooperation with BRD4.
Chen N; Golczer G; Ghose S; Lin B; Langenbucher A; Webb J; Bhanot H; Abt NB; Lin D; Varvares M; Sattler M; Egloff AM; Joh R; Uppaluri R; Emerick KS; Lawrence MS; Saladi SV
Cell Rep; 2022 Jun; 39(11):110970. PubMed ID: 35705032
[TBL] [Abstract] [Full Text] [Related]
4. AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer.
Iida M; McDaniel NK; Kostecki KL; Welke NB; Kranjac CA; Liu P; Longhurst C; Bruce JY; Hong S; Salgia R; Wheeler DL
BMC Cancer; 2022 Apr; 22(1):447. PubMed ID: 35461210
[TBL] [Abstract] [Full Text] [Related]
5. RENORT: a project to analyze patterns of care in radiation oncology in Spain.
López-Torrecilla J; Palacios Eito A; Gómez-Caamaño A; Salinas Ramos J; Samper Ots P; Rodríguez Pérez A
Clin Transl Oncol; 2022 Jul; 24(7):1322-1332. PubMed ID: 35028930
[TBL] [Abstract] [Full Text] [Related]
6. Pattern of care in radiotherapy at a University Hospital in Spain: the RENORT project.
López-Torrecilla J; González Sanchis D; Granero Cabañero D; García Miragall E; Almendros Blanco P; Hernandez Machancoses A; Brualla González L; Pastor Peidro J; Gordo Partearroyo JC; Rosello Ferrando J
Clin Transl Oncol; 2021 Aug; 23(8):1657-1665. PubMed ID: 33586123
[TBL] [Abstract] [Full Text] [Related]
7. Using the Patient Concerns Inventory in the identification of fatigue following treatment for head and neck cancer.
Rogers SN; Semple CJ; Humphris GM; Lowe D; Kanatas A
Int J Oral Maxillofac Surg; 2021 Jul; 50(7):865-872. PubMed ID: 33250271
[TBL] [Abstract] [Full Text] [Related]
8. Development of a novel 7 immune-related genes prognostic model for oral cancer: A study based on TCGA database.
Zhao XT; Zhu Y; Zhou JF; Gao YJ; Liu FZ
Oral Oncol; 2021 Jan; 112():105088. PubMed ID: 33220636
[TBL] [Abstract] [Full Text] [Related]
9. Applying nomograms based on the surveillance, epidemiology and end results database to predict long-term overall survival and cancer-specific survival in patients with oropharyngeal squamous cell carcinomas: A case-control research.
Wang F; Wen J; Yang X; Jia T; Du F; Wei J
Medicine (Baltimore); 2020 Jul; 99(30):e20703. PubMed ID: 32791664
[TBL] [Abstract] [Full Text] [Related]
10. Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in head and neck Squamous Cell Carcinoma Patients.
Duvvuri U; George J; Kim S; Alvarado D; Neumeister VM; Chenna A; Gedrich R; Hawthorne T; LaVallee T; Grandis JR; Bauman JE
Clin Cancer Res; 2019 Oct; 25(19):5752-5758. PubMed ID: 31308059
[TBL] [Abstract] [Full Text] [Related]
11. Development of a Radiation Oncology-Specific Prospective Data Registry for Research and Quality Improvement: A Clinical Workflow-Based Solution.
Chen AM; Kupelian PA; Wang PC; Steinberg ML
JCO Clin Cancer Inform; 2018 Dec; 2():1-9. PubMed ID: 30652556
[TBL] [Abstract] [Full Text] [Related]
12. nrg1 regulates redox homeostasis via NRF2 in papillary thyroid cancer.
Zhang TT; Qu N; Sun GH; Zhang L; Wang YJ; Mu XM; Wei WJ; Wang YL; Wang Y; Ji QH; Zhu YX; Shi RL
Int J Oncol; 2018 Aug; 53(2):685-693. PubMed ID: 29901070
[TBL] [Abstract] [Full Text] [Related]
13. Response to ERBB3-Directed Targeted Therapy in
Drilon A; Somwar R; Mangatt BP; Edgren H; Desmeules P; Ruusulehto A; Smith RS; Delasos L; Vojnic M; Plodkowski AJ; Sabari J; Ng K; Montecalvo J; Chang J; Tai H; Lockwood WW; Martinez V; Riely GJ; Rudin CM; Kris MG; Arcila ME; Matheny C; Benayed R; Rekhtman N; Ladanyi M; Ganji G
Cancer Discov; 2018 Jun; 8(6):686-695. PubMed ID: 29610121
[No Abstract] [Full Text] [Related]
14. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
[TBL] [Abstract] [Full Text] [Related]
15. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract] [Full Text] [Related]
16. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
Jimeno A; Machiels JP; Wirth L; Specenier P; Seiwert TY; Mardjuadi F; Wang X; Kapp AV; Royer-Joo S; Penuel E; McCall B; Pirzkall A; Clement PM
Cancer; 2016 Dec; 122(24):3803-3811. PubMed ID: 27525588
[TBL] [Abstract] [Full Text] [Related]
17. Identifying patients with suspected gastro-oesophageal cancer in primary care: derivation and validation of an algorithm.
Hippisley-Cox J; Coupland C
Br J Gen Pract; 2011 Nov; 61(592):e707-14. PubMed ID: 22054334
[TBL] [Abstract] [Full Text] [Related]
18. Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models.
Oliveras-Ferraros C; Vazquez-Martin A; Queralt B; Adrados M; Ortiz R; Cufí S; Hernández-Yagüe X; Guardeño R; Báez L; Martin-Castillo B; Pérez-Martínez MC; Lopez-Bonet E; De Llorens R; Bernadó L; Brunet J; Menendez JA
Int J Oncol; 2011 Dec; 39(6):1455-79. PubMed ID: 21833472
[TBL] [Abstract] [Full Text] [Related]
19. Transoral laser microsurgery outcomes with early glottic cancer: the Dalhousie University experience.
Lester SE; Rigby MH; Taylor SM
J Laryngol Otol; 2011 May; 125(5):509-12. PubMed ID: 21281534
[TBL] [Abstract] [Full Text] [Related]
20. Nurse led electronic toxicity scoring in head and neck radiotherapy.
Fox E; Barrett-McNeil K; Khoo LH; Middleton M
Eur J Oncol Nurs; 2011 Apr; 15(2):112-7. PubMed ID: 20678960
[TBL] [Abstract] [Full Text] [Related]
[Next]
